Jad Chahoud Shared CONKO-007 Trial Results
Jad Chahoud, Genitourinary Medical Oncologist at Moffitt Cancer Center, shared a recent article by Rainer Fietkau and colleagues on X:
“CONKO-007 (JCO): Post-induction chemo vs CRT in unresectable PDAC, CRT didn’t improve R0 rate nor OS. Among surgical patients, R0 was higher with CRT (69% vs 50%). Margin gains ≠ survival—where does CRT fit?”
Title: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial
Authors: Rainer Fietkau, Michael Ghadimi, Robert Grützmann, Uwe A. Wittel, Lutz Jacobasch, Waldemar Uhl, Roland S. Croner, Wolf Otto Bechstein, Ulf Peter Neumann, Dirk Waldschmidt, Stefan Boeck, Nicolas Moosmann, Anke C. Reinacher-Schick, Henriette Golcher, Werner Adler, Sabine Semrau, Dorota Lubgan, Annett Kallies, Markus Hecht, Iris Tischoff, Andrea Tannapfel, Benjamin Frey, Helmut Oettle
More posts featuring Jad Chahoud on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023